
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
10/22/2026
0:00
2:53
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
More episodes from "Pharmaceutical Executive"



Don't miss an episode of “Pharmaceutical Executive” and subscribe to it in the GetPodcast app.








